bioAffinity Technologies proudly will present at Advancing Early Lung Cancer Detection at the Cleveland Clinic, an invitation-only symposium that brings together clinical experts, advocacy groups and industry leaders working to advance new technologies and methods necessary to find lung cancer at its earliest stages.
read moreSan Antonio, TX (March 12, 2019) bioAffinity Technologies, a privately held biotech company, today announced the formation of a Scientific and Medical Advisory (SMA) Board to provide independent expert advice and counsel on the Company’s research and development of innovative cancer diagnostics and therapeutics, including CyPath® Lung.
read moreSan Antonio, TX (March 6, 2019) Healthcare innovators Lyfebulb and Helsinn selected bioAffinity Technologies, a privately held biotech company developing diagnostics and therapeutics for cancer, as one of 10 finalists for the second annual in Oncology. The Innovation Award recognizes groundbreaking work to advance the prevention and management of cancer.
read moreBioAffinity Technologies is proud to be named a finalist in the Lyfebulb Helsinn 2019 Innovation Summit in Oncology, March 18 and 19, 2019 in Monaco.
read moreSAN ANTONIO, TX (February 4, 2019) bioAffinity Technologies, a privately held biotech company, announced that the Canadian Intellectual Property Office has awarded a patent expanding the Company’s claims associated with its proprietary CyPath© technology for the early detection of cancer.
read more